Advancing the Development of Therapeutics Through Rare Disease Patient Community Engagement

The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public meeting entitled "Advancing the Development of Therapeutics Through Rare Disease Patient Community Engagement." Convened by the Duke-Robert J. Margolis, MD Center for Health Policy (Duke-Margolis) in collaboration with FDA and supported by a cooperative agreement between FDA and Duke-Margolis, the workshop will focus on how best to understand patients' experiences living with a rare disease and how to incorporate those experiences, as well as patients' priorities for treatment goals, throughout the drug development process.

Abstract as published in the Federal Register.

The complete document — every provision, the docket, and the comment instructions — is published in the Federal Register. SPEQ surfaces and indexes it for reference; the authoritative text lives on federalregister.gov.